Wednesday, July 16, 2025 7/16/2025

JOC-x: Chemotherapy conjugates that open tumor tight junctions to treat cancer

Award Number: R43CA206607
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/20/2016
PERIOD OF PERFORMANCE END DATE: 12/31/2017

Group Awards By:

View Award Description

JOC-x: Chemotherapy conjugates that open tumor tight junctions to treat cancer - Project Summary Tumors survive cancer therapy in part by blocking the entrance and permeation of drugs into the cancer. We have developed a conjugatable therapeutic, “JOC-x”, that selectively opens up tumor tight junctions, which dramatically enhances penetration. This results in markedly increased concentrations of cancer drugs in the tumor. JOC-x may allow doctors to treat patients with cancer drugs at increased doses, which directly correlates with enhanced therapeutic effects. At the same time, it could reduce or eliminate the side effects of cancer therapy and address one of the major needs of the current state-of-the-art: Developing therapies that are both more effective and less toxic. Importantly, JOC-x can be used to improve clinical outcomes with cancer drugs that are already on the market as well as the next generation of cancer drugs. The goal of this proposal is to develop and test a JOC-x conjugate formed by linking the tumor- targeting tight junction opener with a chemotherapeutic agent through a polymeric backbone. The targeting and enhancing construct (1) Will be targeted to tumors (2) Will open the tumor microenvironment (3) Will therefore allow for dramatic levels of drug accumulation (4) Will result in increased killing of tumor cells and improved clinical efficacy We will do this research in two straightforward steps: we will first produce and characterize JOC-x conjugates and then we will test the conjugates for enhanced therapeutic efficacy in animal models of ovarian cancer. If we are successful, we will further move this new type of therapy towards clinical testing in humans.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2018 ( Subtotal = $0 )
2018	2016	PAI LIFE SCIENCES, INC.	1616 EASTLAKE AVE E STE 550	SEATTLE	WA	98102	KING	USA	Cancer Treatment Research	000	1	5/22/2018	NEW	$0
														Subtotal = $0

Issue Date FY: 2016 ( Subtotal = $199,997 )
2016	2016	PROTEIN ADVANCES INC	1124 COLUMBIA STREET	POINEER SQUARE	WA	98104		USA	Cancer Treatment Research	000	1	9/20/2016	NEW	$199,997
														Subtotal = $199,997

Grand Total All Awards = $199,997

Top

All Categories

About

Search

Reports

Data Submission

Award Information

JOC-x: Chemotherapy conjugates that open tumor tight junctions to treat cancer

Award Number: R43CA206607

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/20/2016

PERIOD OF PERFORMANCE END DATE: 12/31/2017

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer